JP2014500312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500312A5 JP2014500312A5 JP2013546073A JP2013546073A JP2014500312A5 JP 2014500312 A5 JP2014500312 A5 JP 2014500312A5 JP 2013546073 A JP2013546073 A JP 2013546073A JP 2013546073 A JP2013546073 A JP 2013546073A JP 2014500312 A5 JP2014500312 A5 JP 2014500312A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- zebralin
- human chorionic
- chorionic gonadotropin
- inducer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 108010074328 Interferon-gamma Chemical class 0.000 claims 17
- 102000008070 Interferon-gamma Human genes 0.000 claims 17
- 229960003130 interferon gamma Drugs 0.000 claims 17
- 102000014150 Interferons Human genes 0.000 claims 12
- 108010050904 Interferons Proteins 0.000 claims 12
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 11
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 11
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 11
- 229940079322 interferon Drugs 0.000 claims 11
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 10
- 239000000411 inducer Substances 0.000 claims 9
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 8
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 8
- 206010036790 Productive cough Diseases 0.000 claims 6
- 210000003802 sputum Anatomy 0.000 claims 6
- 208000024794 sputum Diseases 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 4
- 238000004113 cell culture Methods 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Chemical class 0.000 claims 3
- 102000001895 Gonadotropin Receptors Human genes 0.000 claims 2
- 108010040490 Gonadotropin Receptors Proteins 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- -1 zebralin Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 239000012979 RPMI medium Substances 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1051356-2 | 2010-12-22 | ||
| SE1051356 | 2010-12-22 | ||
| PCT/SE2011/051544 WO2012087234A1 (en) | 2010-12-22 | 2011-12-20 | A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500312A JP2014500312A (ja) | 2014-01-09 |
| JP2014500312A5 true JP2014500312A5 (enExample) | 2015-02-19 |
| JP6063392B2 JP6063392B2 (ja) | 2017-01-18 |
Family
ID=46314247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546073A Expired - Fee Related JP6063392B2 (ja) | 2010-12-22 | 2011-12-20 | 自己免疫性障害または臓器免疫拒絶による苦痛を治療するための、インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）を誘導する少なくとも２つの化合物を含んでなる組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20130309198A1 (enExample) |
| EP (2) | EP3238726A3 (enExample) |
| JP (1) | JP6063392B2 (enExample) |
| CA (1) | CA2822745A1 (enExample) |
| DK (1) | DK2654758T3 (enExample) |
| ES (1) | ES2638818T3 (enExample) |
| PL (1) | PL2654758T3 (enExample) |
| WO (1) | WO2012087234A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016528197A (ja) * | 2013-07-01 | 2016-09-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| GB201504701D0 (en) * | 2015-03-19 | 2015-05-06 | Idogen Ab | Novel treatment method |
| CN104873731A (zh) * | 2015-05-22 | 2015-09-02 | 宫兆妮 | 用于狼疮肾炎的中药 |
| EP3503897A1 (en) * | 2016-08-26 | 2019-07-03 | Idogen AB | Ex vivo methods of inducing ido expression in antigen presenting cells using a compound selected from the group consisting of azacytidine, and decitabine |
| US11591300B2 (en) | 2017-12-21 | 2023-02-28 | The Brigham And Women's Hospital, Inc. | Oxazole containing compounds as activators of IDO1 and AhR |
| US11712425B2 (en) | 2018-03-14 | 2023-08-01 | Albert Einstein College Of Medicine | Immunoregulatory role of 3-OH-kynurenamine and uses thereof |
| EP4096720A2 (en) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| WO2024033896A1 (en) * | 2022-08-12 | 2024-02-15 | Biorchestra Co., Ltd. | Oligonucleotides targeting indoleamine 2,3-dioxygenase and uses thereof |
| US20240238384A1 (en) * | 2023-01-17 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518012B1 (en) * | 1999-04-02 | 2003-02-11 | Health Research, Inc. | Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| WO2006105979A1 (en) * | 2005-04-07 | 2006-10-12 | Nycomed Gmbh | Sulfonylpyrroles as histone deacetylase inhibitors |
| PL2559690T3 (pl) * | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| EP1907856A2 (en) * | 2005-07-27 | 2008-04-09 | Oncomethylome Sciences SA | Angiogenesis inhibition based upon icam 1 or junb expression levels |
| EP2164500B1 (en) | 2007-05-25 | 2013-12-04 | Idogen AB | The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
-
2011
- 2011-12-20 CA CA2822745A patent/CA2822745A1/en not_active Abandoned
- 2011-12-20 EP EP17166929.4A patent/EP3238726A3/en not_active Withdrawn
- 2011-12-20 EP EP11850142.8A patent/EP2654758B1/en not_active Not-in-force
- 2011-12-20 WO PCT/SE2011/051544 patent/WO2012087234A1/en not_active Ceased
- 2011-12-20 ES ES11850142.8T patent/ES2638818T3/es active Active
- 2011-12-20 JP JP2013546073A patent/JP6063392B2/ja not_active Expired - Fee Related
- 2011-12-20 US US13/997,356 patent/US20130309198A1/en not_active Abandoned
- 2011-12-20 DK DK11850142.8T patent/DK2654758T3/en active
- 2011-12-20 PL PL11850142T patent/PL2654758T3/pl unknown
-
2014
- 2014-11-25 US US14/553,098 patent/US9839674B2/en not_active Expired - Fee Related
-
2017
- 2017-10-16 US US15/785,075 patent/US20180028621A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| PH12014501134B1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| JP2016511753A5 (enExample) | ||
| MX2022015612A (es) | Nucleotidos de purina beta-d-2'-desoxi-2'-alfa-fluoro-2'-beta-c-su stituidos-2-modificados-n6-sustituidos para el tratamiento del virus de la hepatitis c. | |
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| UA108221C2 (uk) | Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae | |
| EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
| MD20140134A2 (ro) | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice | |
| JP2015143248A5 (enExample) | ||
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| EA201391127A1 (ru) | C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| JP2013509429A5 (enExample) | ||
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| JP2017524735A5 (enExample) | ||
| AR088294A1 (es) | Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| WO2017077528A3 (en) | Methods and pharmaceutical compositions for treatment of lung inflammation | |
| PH12015502589A1 (en) | 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives | |
| BR112012021291A2 (pt) | inibidores diméricos de iap. | |
| EP2694692A4 (en) | ALUMINUM ALLOY COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF BY PRESSURE DIE CASTING | |
| EP3238726A3 (en) | Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone | |
| BR112016000874A2 (pt) | vírus de rna oncolítico geneticamente estável, método de fabricação e uso dos mesmos | |
| BR112015029947A2 (pt) | composições e métodos para liberação de nutriente | |
| JP2013501511A5 (enExample) | ||
| JP2013529628A5 (enExample) |